Press releases
Regulatory
May 19, 2022
Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue
Regulatory
April 26, 2022
Interim report January-March 2022
Regulatory
March 21, 2022
Regulatory
February 17, 2022
Significant progress towards Emcitate® marketing applications in the US and Europe in 2023
Regulatory
January 18, 2022
Regulatory
December 13, 2021
Regulatory
November 4, 2021
Interim report January-September 2021
Regulatory
August 19, 2021
Emcitate development program progressing according to plan
Regulatory
April 19, 2021
Egetis Therapeutics appoints Yilmaz Mahshid as new CFO
Regulatory
March 26, 2021
Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics